drugset / Trial / NCT04975269

Acetazolamide Trial in Normal Pressure Hydrocephalus

NCT04975269

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A pharmacological treatment to patients with normal pressure hydrocephalus (NPH) is missing. The aim is to investigate if acetazolamide given to patients with NPH improves gait function and study the pathophysiological mechanisms leading to reduced symptoms. Patients will be randomized to acetazolamide or placebo and duration of treatment will be from diagnosis to the day of shunt surgery. Target dose is 500 mg/day. Study design is a double-blind randomized controlled trial and the plan is to include 42-50 patients. The study is investigator-initiated without financial sponsorship from the industry.

Timeline

Start
2022-02-17
Primary completion
2024-11-18
Completion
2026-04-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetazolamide Small molecule 250 mg Oral